IV Caldolor

ApprovedSmall molecule

SSt. Joseph's Hospital and Medical Center, Phoenix

IV Caldolor is one of 13 small molecule programs targeting Pituitary Tumor. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pituitary TumorActive, not recruiting

Pituitary TumorApproved

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Pituitary Tumor

#DrugCompanyPhaseTrials

Signifor

Dostinex

1 3

Tykerb

GSK

Phase 2

1 4

Opdivo

Bristol-Myers Squibb

Phase 2

1 5

Yervoy

Bristol-Myers Squibb

Phase 2

1 6

Sandostatin

Novartis

Phase 2

—7

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 8

Rosiglitazone Maleate

GSK

Phase 2

2 9

Pasireotide LAR

Novartis

Phase 2

1 10

IV Caldolor

SSt. Joseph's Hospital and Medical Center, Phoenix

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pituitary Tumor1 trial

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 4·NCT02351700·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IV Caldolor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV Caldolor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV Caldolor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Joseph's Hospital and Medical Center, Phoenix company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSt. Joseph's Hospital and Medical Center, Phoenix

IV Caldolor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pituitary Tumor1 trial

References

Drug Info

Quick Facts

Related News